SG193612A1 - Benzoic acid salt of otamixaban - Google Patents
Benzoic acid salt of otamixaban Download PDFInfo
- Publication number
- SG193612A1 SG193612A1 SG2013071766A SG2013071766A SG193612A1 SG 193612 A1 SG193612 A1 SG 193612A1 SG 2013071766 A SG2013071766 A SG 2013071766A SG 2013071766 A SG2013071766 A SG 2013071766A SG 193612 A1 SG193612 A1 SG 193612A1
- Authority
- SG
- Singapore
- Prior art keywords
- benzoic acid
- methyl
- acid salt
- amino
- oxidopyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305348 | 2011-03-29 | ||
| US201161500342P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/055364 WO2012130821A1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG193612A1 true SG193612A1 (en) | 2013-11-29 |
Family
ID=44065390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013071766A SG193612A1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Country Status (21)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012130819A1 (en) | 2011-03-29 | 2012-10-04 | Sanofi | Otamixaban formulations with improved stability |
| CN106565698B (zh) * | 2016-08-15 | 2019-03-08 | 南京帕隆材料科技有限公司 | 取代噻唑类衍生物及其制备方法和用途 |
| CN106518859B (zh) * | 2016-08-15 | 2019-01-18 | 南京帕隆材料科技有限公司 | 噻唑类衍生物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| CZ297544B6 (cs) * | 1996-01-02 | 2007-02-07 | Aventis Pharmaceuticals Inc. | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy |
| GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| NZ599556A (en) * | 2007-05-02 | 2013-10-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| BR112012001900A2 (pt) * | 2009-07-29 | 2016-03-15 | Sanofi Sa | otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st |
-
2012
- 2012-03-27 MX MX2013011266A patent/MX2013011266A/es active IP Right Grant
- 2012-03-27 US US14/008,332 patent/US8993602B2/en active Active
- 2012-03-27 KR KR1020137028416A patent/KR101852226B1/ko not_active Expired - Fee Related
- 2012-03-27 PL PL12711858T patent/PL2691371T3/pl unknown
- 2012-03-27 CN CN201280026534.0A patent/CN103562183B/zh active Active
- 2012-03-27 WO PCT/EP2012/055364 patent/WO2012130821A1/en not_active Ceased
- 2012-03-27 JP JP2014501569A patent/JP5959617B2/ja active Active
- 2012-03-27 HR HRP20150613TT patent/HRP20150613T1/hr unknown
- 2012-03-27 RU RU2013148005/04A patent/RU2597423C2/ru not_active IP Right Cessation
- 2012-03-27 EP EP12711858.6A patent/EP2691371B1/en active Active
- 2012-03-27 PT PT127118586T patent/PT2691371E/pt unknown
- 2012-03-27 SG SG2013071766A patent/SG193612A1/en unknown
- 2012-03-27 SI SI201230219T patent/SI2691371T1/sl unknown
- 2012-03-27 MY MYPI2013003459A patent/MY161396A/en unknown
- 2012-03-27 DK DK12711858.6T patent/DK2691371T3/da active
- 2012-03-27 ES ES12711858.6T patent/ES2539236T3/es active Active
- 2012-03-27 BR BR112013025105A patent/BR112013025105A2/pt not_active Application Discontinuation
- 2012-03-27 AU AU2012234325A patent/AU2012234325B2/en not_active Ceased
- 2012-03-27 CA CA2830965A patent/CA2830965C/en not_active Expired - Fee Related
-
2013
- 2013-09-29 IL IL228574A patent/IL228574A/en active IP Right Grant
-
2015
- 2015-06-17 CY CY20151100521T patent/CY1116659T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY161396A (en) | 2017-04-14 |
| RU2597423C2 (ru) | 2016-09-10 |
| IL228574A0 (en) | 2013-12-31 |
| CA2830965C (en) | 2019-04-09 |
| RU2013148005A (ru) | 2015-05-10 |
| KR101852226B1 (ko) | 2018-04-25 |
| AU2012234325B2 (en) | 2016-08-11 |
| CY1116659T1 (el) | 2017-03-15 |
| EP2691371A1 (en) | 2014-02-05 |
| US8993602B2 (en) | 2015-03-31 |
| US20140024684A1 (en) | 2014-01-23 |
| BR112013025105A2 (pt) | 2017-06-06 |
| EP2691371B1 (en) | 2015-03-18 |
| HK1189584A1 (en) | 2014-06-13 |
| JP5959617B2 (ja) | 2016-08-02 |
| WO2012130821A1 (en) | 2012-10-04 |
| KR20140022851A (ko) | 2014-02-25 |
| MX2013011266A (es) | 2014-03-27 |
| SI2691371T1 (sl) | 2015-07-31 |
| AU2012234325A1 (en) | 2013-10-17 |
| ES2539236T3 (es) | 2015-06-29 |
| PL2691371T3 (pl) | 2015-08-31 |
| CN103562183B (zh) | 2015-12-23 |
| PT2691371E (pt) | 2015-07-20 |
| DK2691371T3 (da) | 2015-06-22 |
| IL228574A (en) | 2015-07-30 |
| CN103562183A (zh) | 2014-02-05 |
| HRP20150613T1 (hr) | 2015-07-17 |
| JP2014509622A (ja) | 2014-04-21 |
| CA2830965A1 (en) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103261161B (zh) | 凝血因子Xa抑制剂的结晶形式 | |
| CA2830965C (en) | Benzoic acid salt of otamixaban | |
| IL297206A (en) | Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one | |
| US7829711B2 (en) | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione | |
| CA2424565C (en) | Novel crystalline forms of a factor xa inhibitor | |
| CA3180417A1 (en) | Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid | |
| HK1189584B (en) | Benzoic acid salt of otamixaban | |
| AU2005317158A1 (en) | Crystalline forms of a factor Xa inhibitor | |
| WO2006036927A1 (en) | Crytalline forms of a pyrazolo `3, 4-c ! pyridine factor xa inhibitor | |
| CN110759901A (zh) | 四氢异喹啉类衍生物及其制备方法和用途 | |
| US20140329864A1 (en) | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid | |
| KR20180124428A (ko) | 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| US20140343106A1 (en) | Sodium Salt Of (R)-3-[6-Amino-Pyridin-3-Yl]-2-(1-Cyclohexyl-1H-Imidazol-4-Yl)-Propionic Acid | |
| KR20160042107A (ko) | 시스테인 프로테아제 억제제로서 유용한 n-[1-6-(에티닐-3-옥소-헥사하이드로-푸로[3,2-b]피롤-4-카르보닐)-3-메틸-부틸]-4-[5-플루오로-2-(4-메틸-피페라지닐)티아졸-4-일]-벤즈아미드의 염의 2형 결정질 다형체 | |
| JP2025533955A (ja) | （２ｓ，５ｒ）－５－（２－クロロフェニル）－１－（２’－メトキシ－［１，１’－ビフェニル］－４－カルボニル）ピロリジン－２－カルボン酸の多形およびその調製プロセス | |
| CA3261470A1 (en) | N-[4-(4-[[2-(DIMETHYLAMINO)ETHYL]AMINO]-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)-2-FLUOROPHENYL]-2,5-DIFLOOROBENZENESULFONAMIDE SALTS AND THEIR CRYSTALLINE FORMS |